roxindole

Also Known As:

3-(4-(3,6-Dihydro-4-phenyl-1(2H)-pyridinyl)butyl)-1H-indol-5-ol; 5-hydroxy-3-(4-(4-phenyl-1,2,3,6-tetrahydropyidyl)-1-butyl)-1-indole mesylate; EMD 49980; EMD-49980; roxindol; roxindole hydrochloride; roxindole mesylate; roxindole monohydrochloride; 1H-Indol-5-ol, 3-(4-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)butyl)-

Networked: 8 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198

Related Diseases

1.	Dyskinesias (Dyskinesia) 04/01/1993 - "EMD 49980 monotherapy resulted in a mild improvement in parkinsonian symptoms, but when co-administered with levodopa, had no significant effect on dyskinesias or on the antiparkinsonian effect of the dopamine precursor. " 04/01/1993 - "These results suggest that EMD 49980 exerts a net weak dopamine agonist effect but fails to ameliorate levodopa-induced dyskinesias."
2.	Schizophrenia (Dementia Praecox) 03/01/1992 - "Early clinical results with the neuroleptic roxindole (EMD 49,980) in the treatment of schizophrenia--an open study." 03/01/1992 - "The neuroleptic effect and tolerability of roxindole (EMD 49,980), an agonist of the dopamine-D2 autoreceptor, was studied during a 4 week treatment period in 7 patients with paranoid-hallucinatory schizophrenia (ICD-9: 295.3). " 07/01/1991 - "In view of the only moderate antipsychotic efficacy in acute schizophrenia and the fact that antidepressant and anxiolytic effects were also observed, a clinical investigation of EMD 49980 in affective disorders and in schizophrenia with depression or anergia should be performed."
3.	Aphasia (Dysphasia) 11/01/1992 - "Current evidence from pilot studies suggests that dopamine autoreceptor agonists like roxindole may produce a minor to moderate improvement of symptoms like affective flattening, depressed mood, alogia, and avolition, possibly by stimulation of supersensitive postsynaptic dopamine receptors. " 01/01/1995 - "Current evidence from several open and one placebo-controlled clinical trial suggests that some dopamine autoreceptor agonists like pramipexole, roxindole and talipexole may produce a mild improvement of symptoms like affective flattening, depressed mood, alogia and avolition. "
4.	Mood Disorders (Mood Disorder) 07/01/1991 - "In view of the only moderate antipsychotic efficacy in acute schizophrenia and the fact that antidepressant and anxiolytic effects were also observed, a clinical investigation of EMD 49980 in affective disorders and in schizophrenia with depression or anergia should be performed."
5.	Prolactinoma (Prolactinomas) 06/01/1994 - "Ten patients with prolactin-secreting pituitary adenomas received roxindol three times daily at a dosage of 7.5-30 mg/day for at least 4 weeks according to a prospective protocol. " 06/01/1994 - "We studied the effects of the new non-ergot D2-dopamine agonist roxindol for the treatment of human prolactinomas. " 06/01/1994 - "Thus, for the first time we could show a suppressive effect of roxindol on prolactin secretion in human prolactinomas. " 06/01/1994 - "Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: first results."

Related Drugs and Biologics

1.	Dopamine (Intropin)
2.	Levodopa (L Dopa)
3.	Antipsychotic Agents (Antipsychotics)
4.	Autoreceptors
5.	Dopamine Agonists (Dopamine Agonist)
6.	Anti-Anxiety Agents (Anxiolytics)
7.	Reserpine (Serpasil)
8.	Dopamine Receptors (Dopamine Receptor)
9.	Prolactin
10.	Naloxone (Narcan)